Scilex Holding Company (SCLX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SCLX
- Company Scilex Holding Company
- Price $2.8
- Changes Percentage -4.11
- Change -0.12
- Day Low $2.8
- Day High $2.95
- Year High $19.24
- Year Low $2.62
- Market Cap $41,946,874
- Price Avg 50 EMA (D) $6.21
- Price Avg 200 EMA (D) $6.1
- Exchange NASDAQ
- Volume 27,349
- Average Volume 96,734
- Open $2.81
- Previous Close $2.92
- EPS -38.95
- PE -0.13
- Earnings Announcement 2026-12-02 12:00:00
- Shares Outstanding $8,491,270
Company brief: SCILEX HOLDING COMPANY (SCLX )
- Healthcare
- Drug Manufacturers - General
- Mr. Jaisim Shah
- https://www.scilexholding.com
- US
- N/A
- 03-05-2021
- US80880W1062
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.